Covaccine may soon get WHO approval, Chief Scientist said this


The campaign to give corona vaccine to the people in India is progressing at a fast pace. Meanwhile, good news has come out for India’s vaccine manufacturer Bharat Biotech. In fact, Dr. Soumya Swaminathan, Chief Scientist of the World Health Organization (WHO), has considered Bharat Biotech’s Kovid-19 vaccine to be very effective. The vaccine manufacturing company has also been waiting for the approval of the World Health Organization for a long time.

WHO Chief Scientist Dr. Soumya Swaminathan said on Friday that the data of Bharat Biotech’s vaccine trial of Covaccine seems to be correct. He said that a pre-submission meeting was also held on June 23. The safety profile of Covaccine so far is meeting WHO standards.

Dr. Soumya Swaminathan gave this great information

During an interview, he said, “The data from the Phase III trial of the vaccine is good. Its efficiency is very high. The effect of the vaccine against the delta variant is very low, but still it is very good.” He further said, “Except for America, there has been an increase in the cases of corona in most parts of the world. At the same time, there has been no decrease in the cases of deaths.” Swaminathan also suggested primary vaccination of at least 60-70 per cent of the population in India. He said that WHO is taking every step to eliminate Kovid-19 completely.

The results of the third phase trial of Covaccine came out

Significantly, the results of the third phase trial of Covaccine have been revealed. Bharat Biotech said that it has analyzed the data of the final phase-3 for the vaccine and its covaccine has been found to be effective in severe patients of corona and patients of delta variant.

read this also :-

Bangladesh Factory Fire: 52 killed, at least 50 injured in a massive fire at a factory in Bangladesh

Haiti President Assassination: American man, Colombian ex-serviceman arrested in connection with the assassination of Haiti’s President

.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles

You cannot copy content of this page